Amarin Corp Plc (AMRN)

[retinadoc]

This is really bad and frightening. Long COVID patients lose approximately 40% of their capillary capacity.

🚨 Absolutely stunning #LongCovid findings:

"Compared with healthy controls, the capillary density of #LongCovid patients was decreased by 41%"

"Our data strongly suggest that COVID leaves persistent capillary rarefication even 18 months after infection" https://t.co/f8BmW0EJ9k

— charlos (@loscharlos) August 11, 2022

Angiogenesis is a real journal. I believe this accounts for the clinical presentation of the disease. These patients are existing in a perpetual state of tissue hypoxia including the most oxygen dependent organs in the body, the heart and brain. Once these capillary beds are gone, they are gone for good, and the author is correct that this is not reversible. To my knowledge we have no drugs that target the regrowth of microcirculation.

The only option is to protect these vessels and minimize the damage after infection. Based on this finding, Vascepa really should be SOC post COVID. 10% of infected population with this chronic disability will be another public health disaster.

Kiwi, as for doing studies without patent protection in the US. My thoughts: 1) Unlike marketing, small pilot studies are cheap 2) ROW still matters 3) makes Amarin more attractive and valuable to an acquiring BP 4) more MD Vascepa recognition 5) Shuts down the Nissen/Herper greek chorus 6) taking the high road and believing in the awesome potential of this drug will help in the long run even if generics still have significant market share.